Cramer Recommends J&J For Best Big Pharma Pipeline Play
Coming out of the Twittersphere Wednesday afternoon: a trader asks Jim Cramer about a potential big pharma play which could fit into his or her portfolio. The trader specified the play would need to be for over the next five years. Cramer responded:
— Jim Cramer (@jimcramer) March 5, 2014
J&J (NYSE: JNJ) shares do not seem to be responding to the recommendation by Cramer, but are trading at afternoon highs. The stock is down 0.6 percent to $92.74 at last check.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.